Alnylam Pharmaceuticals President and CEO John Maraganore has joined the board of immunotherapeutic developer MacroGenics.
"MacroGenics is a very promising immunotherapeutics company with a therapeutically and commercially attractive development pipeline," Maraganore said in a statement. "The company's innovative engineering platform offers a novel approach to enhancing monoclonal antibody therapeutics and has potential applicability in a wide range of diseases including cancer, autoimmune disorders, infectious disease, and allergy.”
ProNAi Therapeutics, which is developing DNA interference-based therapies, last week named its new scientific advisory board.
Joining the company’s SAB is Tod Woolf, founder and CEO of Ipifini. Woolf previously founded RNAi oligo shop Sequitur, which was acquired by Invitrogen in late 2003 (see RNAi News, 11/7/2003).
Also joining ProNAi’s SAB is Cy Stein, professor and head of genitourological cancer at Albert Einstein College of Medicine and long-time antisense and RNAi researcher.
Other members of ProNAi’s SAB are Mace Rothenberg, professor of medicine at Vanderbilt Medical School; Ayad Al-Katib, head of oncology at St. Johns Medical Center and professor of medicine at Wayne State University Medical School; David Olson, vice president of research at PanCell and co-founder of Gentera; Craig Webb, director of the multiple myeloma laboratory at the Van Andel Research Institute; John Schimenti, professor and director of vertebrate genomics at Cornell University; and Terry Magnuson, professor and chair of genetics at the University of North Carolina, Chapel Hill.